<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03461003</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-17-1014</org_study_id>
    <nct_id>NCT03461003</nct_id>
  </id_info>
  <brief_title>N-of-1 Trials In Children With Hypertension</brief_title>
  <acronym>NICHE</acronym>
  <official_title>A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The single patient (n-of-1) randomized trial is an underused approach to resolving&#xD;
      therapeutic uncertainty by using a patient's own data to inform an individualized treatment&#xD;
      plan. The proposed research is designed to assess whether the n-of-1 trial approach improves&#xD;
      blood pressure control. This trial will advance learning about not only the treatment of&#xD;
      pediatric hypertension but also the use of a neglected type of randomized trial to optimize&#xD;
      the care of each patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pediatric hypertension, a growing problem, often requires prescription of antihypertensive&#xD;
      medication. Pediatric hypertension specialists lack an evidentiary base on which to establish&#xD;
      definitive clinical practice guidelines for first-line therapy. Significant practice&#xD;
      variation is an unsurprising consequence. Routine choice of the same first-line therapy for&#xD;
      most patients with hypertension, absent testing other options, may delay correction of blood&#xD;
      pressure for months or years. Failure to incorporate patient preferences in medical&#xD;
      decision-making may also contribute to decreased patient satisfaction and adherence.&#xD;
&#xD;
      Large parallel-group, comparative effectiveness trials are likely not on the horizon for this&#xD;
      population. Moreover, heterogeneity of treatment effects would minimize the generalizability&#xD;
      of such a trial to all patients.&#xD;
&#xD;
      This is a parallel-group, randomized clinical trial to test whether the n-of-1 trial approach&#xD;
      is superior to usual care in normalizing blood pressure while minimizing exposure to&#xD;
      compliance-reducing side effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Actual">May 2, 2021</completion_date>
  <primary_completion_date type="Actual">November 14, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory blood pressure (BP) control</measure>
    <time_frame>6 months from enrollment</time_frame>
    <description>Normal ambulatory blood pressure by American Heart Association criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulatory BP reduction from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Wake mean systolic BP (baseline) minus wake mean systolic BP (6 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect experience</measure>
    <time_frame>6 months</time_frame>
    <description>Questionnaire regarding overall experience with side effects on current medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the cost-effectiveness of the N-of-1 trial relative to usual care expressed as the incremental health system costs per additional normotensive child. Hypothesis: The N-of-1 trial will be deemed cost effective if it leads to either an increase in BP control without an increase in health system costs, a reduction in costs without a decrease in BP control, or both a reduction in costs with BP control improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Pediatric Hypertension</condition>
  <arm_group>
    <arm_group_label>NICHE method</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the NICHE method, antihypertensive therapy will be chosen using an n-of-trial to identify the preferred therapy. Preferred therapy is defined a priori as that which produces the greatest reduction in ambulatory BP without intolerable side effects. Tested drugs will include amlodipine or losartan, lisinopril, and hydrochlorothiazide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No protocol will be introduced to standardize BP management in the control arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NICHE method</intervention_name>
    <description>Based on underlying comorbidities at enrollment, patients will be assigned to either an unrestricted protocol (amlodipine versus lisinopril) or a restricted protocol (losartan versus lisinopril). Two drugs are tested in randomized order. Failure to achieve BP control at maximum doses of the first two drugs will result in augmentation with a diuretic (hydrochlorothiazide). BP control is assessed with 24 hour ambulatory monitoring at the end of each 2 week treatment period. Side effect tolerability is assessed with a questionnaire.</description>
    <arm_group_label>NICHE method</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Physician preference will dictate choice and adjustment of antihypertensive medication, BP measurement modality, interval between visits, and assessment of side effects.</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Calcium-channel blocker; antihypertensive</description>
    <arm_group_label>NICHE method</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Angiotensin-converting-enzyme (ACE) inhibitor; antihypertensive</description>
    <arm_group_label>NICHE method</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Thiazide diuretic; antihypertensive</description>
    <arm_group_label>NICHE method</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Angiotensin II receptor blocker (ARB); antihypertensive</description>
    <arm_group_label>NICHE method</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  treating physician determines that pharmacologic therapy is indicated for treatment of&#xD;
             hypertension&#xD;
&#xD;
          -  ambulatory hypertension has been confirmed (off meds) within 12 months of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt; 10 years&#xD;
&#xD;
          -  resistant hypertension (requiring â‰¥ 3 drug therapy)&#xD;
&#xD;
          -  absolute contraindication or allergy to any of the tested drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joyce P. Samuel, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 31, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2018</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Joyce Philip Samuel</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 21, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

